Qiyu Biotech

Qiyu Biotechnology (Shanghai) Co., Ltd., which also operates under the name QureBio, is a clinical-stage biopharmaceutical company established in July 2017. The firm was founded by Xiangdong Qu, a scientist with approximately two decades of experience in new drug research and development at prominent U.S. companies, including Amgen, Eli Lilly, and Cell Therapeutics Inc. This background in international pharmaceutical R&D provides the foundation for the company's strategic direction. The core team is composed of scientists with deep expertise in antibody engineering and manufacturing processes.

The company's primary business is the research and development of innovative macromolecular drugs to address unmet clinical needs in refractory cancers, autoimmune diseases, inflammatory disorders, and metabolic diseases. Its operational model is centered on leveraging a proprietary suite of technology platforms to create a pipeline of therapeutic candidates. These platforms include systems for hybridoma antibody humanization, phage display, single-domain antibodies, and antibody engineering, such as its I2T platform for bispecific and multispecific antibodies. Qiyu Biotech's revenue generation model involves advancing its internally developed assets through clinical trials and forming strategic partnerships with other pharmaceutical firms for co-development and commercialization. The company has established collaborations with entities like BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific.

Qiyu Biotech's therapeutic pipeline features several key drug candidates. Its lead product, Q-1802, is a bispecific antibody targeting both Claudin18.2 and PD-L1 for the treatment of solid tumors like gastric cancer. This candidate has received Investigational New Drug (IND) clearance from both U.S. and Chinese regulatory agencies and is advancing through clinical trials. Another significant asset, Q-1801, is a dual-target antibody for SIRPα and PD-L1, which also has clinical trial approvals in the U.S. and China. The company has successfully raised significant capital through multiple funding rounds, including a Series C1 financing of nearly CNY 100 million in June 2025, to advance its clinical programs.

Keywords: macromolecular biopharmaceuticals, antibody drug development, biopharmaceutical R&D, refractory cancer treatment, autoimmune disease therapeutics, bispecific antibodies, protein therapeutics, clinical-stage biotech, Xiangdong Qu, Q-1802, Claudin18.2, PD-L1, SIRPα, drug discovery platforms, antibody engineering, pharma co-development, IND clearance, oncology therapeutics, inflammatory disorders, metabolic disease drugs